These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 38249320)

  • 1. Viloxazine Increases Extracellular Concentrations of Norepinephrine, Dopamine, and Serotonin in the Rat Prefrontal Cortex at Doses Relevant for the Treatment of Attention-Deficit/Hyperactivity Disorder.
    Garcia-Olivares J; Yegla B; Bymaster FP; Earnest J; Koch J; Yu C; Rubin J
    J Exp Pharmacol; 2024; 16():13-24. PubMed ID: 38249320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New Insights into the Mechanism of Action of Viloxazine: Serotonin and Norepinephrine Modulating Properties.
    Yu C; Garcia-Olivares J; Candler S; Schwabe S; Maletic V
    J Exp Pharmacol; 2020; 12():285-300. PubMed ID: 32943948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder.
    Bymaster FP; Katner JS; Nelson DL; Hemrick-Luecke SK; Threlkeld PG; Heiligenstein JH; Morin SM; Gehlert DR; Perry KW
    Neuropsychopharmacology; 2002 Nov; 27(5):699-711. PubMed ID: 12431845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. R-fluoxetine increases extracellular DA, NE, as well as 5-HT in rat prefrontal cortex and hypothalamus: an in vivo microdialysis and receptor binding study.
    Koch S; Perry KW; Nelson DL; Conway RG; Threlkeld PG; Bymaster FP
    Neuropsychopharmacology; 2002 Dec; 27(6):949-59. PubMed ID: 12464452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder.
    Nasser A; Hull JT; Chaturvedi SA; Liranso T; Odebo O; Kosheleff AR; Fry N; Cutler AJ; Rubin J; Schwabe S; Childress A
    CNS Drugs; 2022 Aug; 36(8):897-915. PubMed ID: 35896943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of fluoxetine on the ability of bupropion to modulate extracellular dopamine and norepinephrine concentrations in three mesocorticolimbic areas of rats.
    Li SX; Perry KW; Wong DT
    Neuropharmacology; 2002 Feb; 42(2):181-90. PubMed ID: 11804614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended-Release Viloxazine for the Treatment of Attention-Deficit Hyperactivity Disorder in School-Age Children and Adolescents.
    Raible H; D'Souza MS
    Ann Pharmacother; 2023 Dec; 57(12):1436-1448. PubMed ID: 37021356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A selective dopamine reuptake inhibitor improves prefrontal cortex-dependent cognitive function: potential relevance to attention deficit hyperactivity disorder.
    Schmeichel BE; Zemlan FP; Berridge CW
    Neuropharmacology; 2013 Jan; 64(1):321-8. PubMed ID: 22796428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of acetaldehyde on nicotine-induced transmitter levels in young and adult brain areas.
    Sershen H; Shearman E; Fallon S; Chakraborty G; Smiley J; Lajtha A
    Brain Res Bull; 2009 Aug; 79(6):458-62. PubMed ID: 19389462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating the pharmacokinetics of extended release viloxazine in the treatment of children with attention-deficit/hyperactivity disorder.
    Childress A; Burton S
    Expert Opin Drug Metab Toxicol; 2022 Jun; 18(6):357-366. PubMed ID: 35848085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Asenapine increases dopamine, norepinephrine, and acetylcholine efflux in the rat medial prefrontal cortex and hippocampus.
    Huang M; Li Z; Dai J; Shahid M; Wong EH; Meltzer HY
    Neuropsychopharmacology; 2008 Nov; 33(12):2934-45. PubMed ID: 18418367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective activation of Dopamine D3 receptors and norepinephrine transporter blockade enhances sustained attention.
    Marshall CA; Brodnik ZD; Mortensen OV; Reith MEA; Shumsky JS; Waterhouse BD; España RA; Kortagere S
    Neuropharmacology; 2019 Apr; 148():178-188. PubMed ID: 30633928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum.
    Li XM; Perry KW; Wong DT; Bymaster FP
    Psychopharmacology (Berl); 1998 Mar; 136(2):153-61. PubMed ID: 9551772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the effects of antidepressants on norepinephrine and serotonin concentrations in the rat frontal cortex: an in-vivo microdialysis study.
    Beyer CE; Boikess S; Luo B; Dawson LA
    J Psychopharmacol; 2002 Dec; 16(4):297-304. PubMed ID: 12503828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response of peer relations and social activities to treatment with viloxazine extended-release capsules (Qelbree
    Faraone SV; Gomeni R; Hull JT; Busse GD; Lujan B; Rubin J; Nasser A
    Brain Behav; 2023 Apr; 13(4):e2910. PubMed ID: 36847750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Viloxazine extended-release capsules as an emerging treatment for attention-deficit/hyperactivity disorder in children and adolescents.
    Maletic V; Mattingly GW; Earnest J
    Expert Rev Neurother; 2024 May; 24(5):443-455. PubMed ID: 38502148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nicotine-induced changes in neurotransmitter levels in brain areas associated with cognitive function.
    Singer S; Rossi S; Verzosa S; Hashim A; Lonow R; Cooper T; Sershen H; Lajtha A
    Neurochem Res; 2004 Sep; 29(9):1779-92. PubMed ID: 15453274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurocircuitry underlying the preferential sensitivity of prefrontal catecholamines to low-dose psychostimulants.
    Schmeichel BE; Berridge CW
    Neuropsychopharmacology; 2013 May; 38(6):1078-84. PubMed ID: 23303075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reciprocal effects of combined administration of serotonin, noradrenaline and dopamine reuptake inhibitors on serotonin and dopamine levels in the rat prefrontal cortex: the role of 5-HT1A receptors.
    Weikop P; Kehr J; Scheel-Krüger J
    J Psychopharmacol; 2007 Nov; 21(8):795-804. PubMed ID: 17984160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of alpha1- and alpha2-adrenoreceptors on venlafaxine-induced elevation of extracellular serotonin, noradrenaline and dopamine levels in the rat prefrontal cortex and hippocampus.
    Weikop P; Kehr J; Scheel-Krüger J
    J Psychopharmacol; 2004 Sep; 18(3):395-403. PubMed ID: 15358984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.